RxDoctor Payments Data

Emily Prouet, MD

Ophthalmology · Lafayette, LANPI 1043653439

Payments from drug & device makers

$2,090in general payments, 2019–2025

Across 75 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$459
  • AbbVie$258
  • Glaukos Corporation$229
  • Dompe US, Inc.$144
  • Tarsus Pharmaceuticals, Inc.$128
  • Johnson & Johnson Surgical Vision, Inc.$126
  • plus $747 from 13 others

What the payments were for

  • Food & beverage$1,97895%
  • Education$934%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,090 in reported general payments places this provider in the 50th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$189,585
Medicare patients
611
Services billed
1,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$20,595
Prednisolone Acetate308$13,073
XiidraLifitegrast14$11,220
ProlensaBromfenac Sodium19$6,312
MoxifloxacinMoxifloxacin Hcl257$4,370
Bromfenac Sodium14$3,104
Latanoprost270$2,847
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha104$1,081
Timolol Maleate96$1,027
Brimonidine Tartrate33$979
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$861
Dorzolamide-TimololDorzolamide/Timolol/Pf12$713
Acyclovir25$331
ErythromycinErythromycin Base22$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$258$20,59529 claims
Bausch & Lomb Americas Inc.Xiidra$110$11,22014 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$28$6,31219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →